Clinical Trial

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Protocol Amendment History 1 change
notable Sponsor changed: Replimune Inc. -> Replimune, Inc. 2026-04-19
Trial Details
NCT Number NCT06581406
Lead Sponsor Replimune Inc.
Conditions Metastatic Uveal Melanoma
Enrollment 280 participants
Start Date 2024-12-17
Primary Completion 2030-01 (estimated)
Study Completion 2031-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-02